Last reviewed · How we verify
STX-241
At a glance
| Generic name | STX-241 |
|---|---|
| Also known as | PFL-241 |
| Sponsor | Pierre Fabre Medicament |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- STX-241 CI brief — competitive landscape report
- STX-241 updates RSS · CI watch RSS
- Pierre Fabre Medicament portfolio CI